EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, KURA: Kura Oncology

26 Jan 26 15:59
LAST:

8.575

CHANGE:
 0.06		OPEN:
8.650		HIGH:
8.680		ASK:
12.150		VOLUME:
682.3K
CHG(%):
0.70		PREV:
8.630		LOW:
8.420		BID:
8.050		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Jan 268.5208.6808.4208.5701.19M
23 Jan 268.9909.1758.5908.6301.67M
22 Jan 268.7509.1408.6609.0901.18M
21 Jan 268.6008.7908.4958.7201.24M
20 Jan 268.2408.6968.1308.6001.74M
16 Jan 269.0209.0608.4408.4602.3M
15 Jan 269.3209.4208.8908.9101.07M
14 Jan 269.1409.4309.0109.360899.0K
13 Jan 269.0209.2408.9209.2101.12M
12 Jan 269.3809.3908.9909.1701.52M

PROFILE

Name:Kura Oncology
About:Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:12730 High Bluff Drive, San Diego, CA, United States, 92130
Website:https://kuraoncology.com
CUSIP:50127T109
CIK:0001422143
ISIN:US50127T1097
FIGI:BBG008974342
LEI:5493005QORQTZCZYOP39

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-4.84 
Forward P/E:-4.18 
PEG Ratio:-0.18 
Price to Sales:10.70 
Price to Book:3.58 
Profit Margin:-2.37 
Operating Margin:-4.75 
Return on Assets:-0.23 
Return on Equity:-0.51 
EPS Ratio:-2.60 
Revenue:83.28M 
Shares:87.02M 
Market Cap:746.18M 

TECHNICAL INDICATORS

MA5:8.721.7%
MA10:8.873.5%
MA20:9.4410.1%
MA50:10.4121.4%
MA100:9.8615.0%
MA200:8.096.0%
STO9:11.34 
STO14:5.67 
RSI14:36.02 
WPR14:-92.72 
MTM14:-0.97
ROC14:-0.10 
ATR:0.47 
Week High:9.187.0%
Week Low:8.135.5%
Month High:11.0428.7%
Month Low:8.136.0%
Year High:12.4945.7%
Year Low:5.4158.5%
Volatility:55.06